Company Profile

Company Overview

Mersana Therapeutics, Inc. (Nasdaq: MRSN) is a clinical stage biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) leveraging our highly-differentiated best-in-class drug conjugation platform. Our lead program XMT-1522, an investigational antibody drug conjugate against HER2 expressing tumors, demonstrated superior efficacy in a broad range of pre-clinical models not responsive to available HER2 therapies. Phase 1 clinical studies are underway for XMT-1522 and is being co-developed by Mersana and Takeda. Mersana will be responsible for commercialization in the United States and Canada; Takeda will be responsible throughout the rest of world. A second program, XMT-1536, an investigational antibody drug conjugate against Napi2B expressing tumors, demonstrated in pre-clinical models superior efficacy not achievable with traditional ADC platforms and an IND is expected in late 2017. Mersana is well positioned to continue to grow and advance its pipeline based upon our proprietary ADC platform. Mersana has granted access to its ADC platform for use in a small number of programs to Merck Serono and Takeda. These strategic partners are progressing multiple preclinical programs in close collaboration with Mersana.

Mersana seeks individuals who share our excitement about the possibilities our proprietary drug conjugation platform offers and our commitment to making a difference in patients. At Mersana we have a highly collaborative culture and believe that our collective ability to make a difference exceeds the sum of our individual efforts.